United Therapeutics (UTHR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$487.61-0.54%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · UTHR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -14.5% |
| Our one-year growth estimate | diamond | 6.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 21.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
UTHR — officer change
Dated 2026-07-23
Director — Victor Dzau, M.D.: Dr. Victor Dzau was appointed to the Board of Directors and received standard non-employee director compensation.
Why it matters: Updates on the $2 billion share repurchase program could show management's confidence in the stock. It may also indicate future growth.
Supportive ifThey announced share buybacks of at least $1 billion under the ASR program.
Worry ifThere are no updates or signs of share repurchases in the next quarter.
Why it matters: A drop in sector revenue growth could impact UTHR's growth outlook and investor sentiment.
Worry ifSector revenue growth reported below its median.
Less concerning ifSector revenue growth remains at or above its median.
Why it matters: Revenue growth below 10% would signal a slowdown in company momentum and sector trends.
Worry ifQ2 revenue growth reported below 10% year over year.
Less concerning ifQ2 revenue growth stays at or above 10% year over year.
Why it matters: More share repurchases show management's confidence and can help the share price.
Supportive ifLook for news of more share repurchases beyond the $500 million left.
Worry ifNo further share repurchase announcements or a halt to the current program.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$98 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $230 loss on $10,000 · 2.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,829 loss on $10,000 · 18.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The NDA could help Tyvaso treat idiopathic pulmonary fibrosis. This may increase growth.
Supportive ifUnited Therapeutics plans to submit the NDA to the FDA by summer 2026.
Worry ifThe company delays the NDA submission beyond the end of summer 2026.
Why it matters: Progress on ralinepag could improve the product lineup and boost future revenue.
Supportive ifAnnouncement of the NDA submission for ralinepag to the FDA in the second half of 2026.
Worry ifNo news or delays in ralinepag progress.
Why it matters: Positive revenue growth would show recovery from the recent decline. This supports management's goals.
Supportive ifQ2 2026 total revenues were above $781.5 million. This shows a reversal of the decline.
Worry ifQ2 2026 total revenues were below $781.5 million. This shows ongoing revenue challenges.
Why it matters: The news about the share buyback program shows that management believes in the company's value.
Supportive ifCompletion of the $2 billion share repurchase program by March 2027.
Worry ifManagement may stop or cut back the share buyback program.
Why it matters: Submitting the NDA could help Tyvaso treat idiopathic pulmonary fibrosis. This could boost growth.
Supportive ifA press release will confirm the NDA for Tyvaso by August 31, 2026.
Worry ifNo announcement of the NDA submission by the end of summer 2026.
Why it matters: Tyvaso DPI sales are growing. This shows strong demand and a good strategy.
Supportive ifTyvaso DPI revenue growth exceeds 4% year-over-year in the next quarter.
Worry ifTyvaso DPI revenue growth falls below 0% year-over-year in the next quarter.